Takeda Pharmaceutical (TAK) Non-cash Items (2018 - 2026)

Takeda Pharmaceutical's Non-cash Items history runs 9 years deep, the most recent figure standing at $884.1 million for Q1 2026.

• On a quarterly basis, Non-cash Items fell 50.13% year-over-year to $884.1 million in Q1 2026; TTM through Mar 2026 was $8.1 billion, a 1.91% increase from a year earlier, with the FY2026 full-year figure at $8.1 billion, up 1.73% from the prior year.
• Non-cash Items fell to $884.1 million in Q1 2026 per TAK's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Non-cash Items topped out at $3.6 billion in Q1 2022 and bottomed at $812.7 million in Q2 2022.
• The 5-year median for Non-cash Items is $2.1 billion (2024), against an average of $2.0 billion.
• Across the five-year window, Non-cash Items tumbled 57.32% in 2023 and jumped 101.18% in 2024, its largest moves.
• Year by year, Non-cash Items stood at $3.1 billion in 2022, then tumbled by 57.32% to $1.3 billion in 2023, then soared by 101.18% to $2.6 billion in 2024, then declined by 2.62% to $2.6 billion in 2025, then plunged by 65.58% to $884.1 million in 2026.
• Per Business Quant, the three latest TAK Non-cash Items figures stand at $884.1 million (Q1 2026), $2.6 billion (Q4 2025), and $2.9 billion (Q3 2025).